Amylyx Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of 14,090,000 shares of its common stock at a public price of $35.50 per share. The company expects to raise approximately $471.7 million in net proceeds to fund the potential commercial launch of its product candidate avexitide, as well as for R&D and general corporate purposes.
Key Details
- Offering Terms: The company is issuing 14,090,000 shares of common stock at $35.50 per share. The underwriters have a 30-day option to purchase up to an additional 2,113,500 shares.
- Financial Impact: Net proceeds are estimated at approximately $471.7 million, potentially increasing to $542.5 million if the underwriters' option is exercised in full.
- Use of Proceeds: Funds are intended for the potential U.S. commercial launch of avexitide (if approved), securing manufacturing capacity, research and development, and working capital.
- Timeline: The offering is expected to close on August 21, 2026, subject to customary closing conditions.